PDI - Resultado de Búsqueda

Pamela Victoria Salman Boghikian

Full Professor

Universidad Mayor de Chile

Santiago, Chile

Gastric and breast cancer treatments; Tumor heterogeneity and targeted therapies; Precision oncology; Genomic medicine

Médico cirujano, UNIVERSIDAD DE CHILE. Chile, 1992
Licenciatura en medicina, UNIVERSIDAD DE CHILE. Chile, 1990
Medicina interna, UNIVERSIDAD DE CHILE. Chile, 1995
Oncología Médica, UNIVERSIDAD DE CHILE. Chile, 1999
Entrenamiento de especialización (Oncología), UNIV TEXAS M.D. ANDERSON CANCER CENTER. Chile, 2001

Associate Professor Part Time

UNIVERSIDAD DE CHILE

Medicina

Santiago, Chile

2005 - 2008
Associate Professor Part Time

UNIVERSIDAD DE LOS ANDES

Medicina

Santiago, Chile

2010 - 2020
Full Professor Part Time

UNIVERSIDAD MAYOR

Facultad de Medicina y Ciencias de la Salud

Santiago, Chile

2024 - A la fecha

Head of Oncology Research Protocols Part Time

Fundación Arturo López Pérez

Santiago, Chile

2003 - 2017
Director of the Ethics Committee Part Time

Grupo Oncológico Cooperativo Chileno de Investigación (GOCCHI)

Santiago, Chile

2002 - 2003
Creator and Director of the Clinical Studies Unit Part Time

Fundación Arturo López Pérez

Santiago, Chile

2008 - 2017
Senior Medical Oncologist Part Time

Centro Oncológico OncoVIDA

Santiago, Chile

2020 - 2024
Head of the Clinical Trials Unit Part Time

Centro Oncológico OncoVIDA

Santiago, Chile

2020 - 2024
Senior Medical Oncologist Part Time

Hospital San Juan de Dios

Santiago, Chile

2020 - A la fecha
Deputy Medical Director of the Clinical Studies Unit at COP-U Mayor Part Time

Centro de Oncología de Precisión (COP-U Mayor)

Santiago, Chile

2020 - A la fecha

Supervisión Formal de Estudiantes/Practicantes

Angélica de la Macarena Molina Oñate (Médico Oncólogo) Fundación Arturo López Pérez
Sergio Enrique Panay Serra ((Médico Oncólogot) Fundación Arturo Lopez Perez
Carlos Romero Sanchez (Médico Oncólogo) Centro Oncológico OncoVIDA
Elizabeth Milla Ramirez (Médico Oncólogo) Fundación Arturo López Pérez
Jaime Andres Anabalon Toha (Médico Oncólogo) Clínica Alemana de Santiago
Christopher Joseph Tabilo Heavey (Médico Oncólogo y Hematólogo) Clínica Red Salud


Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09) Formiga, Maria Nirvana; Penkov, Konstantin; Kislov, Nikolay; Vasiliev, Aleksandr; Skare, Nils Gunnar; Hong, Walter; Dai, Stanley; Tang, Lily; Qureshi, Anila; Zalevsky, Jonathan; et al. Article ISI JOURNAL OF CLINICAL ONCOLOGY (2024)
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial Saad, Fred; Vjaters, Egils; Shore, Neal; Olmos, David; Xin, Nianzeng; Pereira de Santana Gomes, Andrea Juliana; de Andrade Mota, Augusto Cesar; Jievaltas, Mindaugas; Ulys, Albertas; Jakubovskis, Maris; et al. Article JOURNAL OF CLINICAL ONCOLOGY (2024)
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial Toker, Sarper Article ISI SCOPUS JAMA Oncology (2024)
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study Gümü?, M.; Olivera Hurtado de Mendoza, M. et al. Article ANNALS OF ONCOLOGY (2024)
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus Garrido, Marcelo Article ISI SCOPUS Future Oncology (2023)
First-Line Pembrolizumab plus Chemotherapy Versus Placebo plus Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826 Monk, Bradley J.; Colombo, Nicoletta; Tewari, Krishnansu S.; Dubot, Coraline; Caceres, M. Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Gumus, Mahmut; de Mendoza, Mivael Olivera Hurtado; Samouelian, Vanessa; et al. Article ISI SCOPUS Journal of Clinical Oncology (2023)
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo- controlled, phase 3 trial Guemues, Mahmut; Mendoza, Mivael Olivera Hurtado de; Nguyen, Allison Martin; Monberg, Matthew J. Article ISI SCOPUS The Lancet Oncology (2023)
KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER Tewari, Krishnansu Sujata; Keefe, Stephen Michael Article ISI INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)
Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma Castillo Gutiérrez, Erika; Janoski De Menezes, Juliana; Shaikh, Anadil; Dolfi, Sonia Article NEJM EVIDENCE (2023)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial (Reprinted from vol 28, pg 1061, 2010) Sternberg, Cora N.; Davis, Ian D.; Mardiak, Jozef; Szczylik, Cezary; Lee, Eunsik; Wagstaff, John; Gladkov, Oleg A.; Kavina, Alexander; Zarba, Juan J.; Chen, Mei; et al. Article ISI SCOPUS Journal of Clinical Oncology (2023)
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliarytract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial Kelley, Robin Kate; Ueno, Makoto; Yoo, Changhoon; Finn, Richard S.; Furuse, Junji; Ren, Zhenggang; Yau, Thomas; Klumpen, Heinz-Josef; Chan, Stephen L.; Ozaka, Masato; et al. Article ISI SCOPUS The Lancet (2023)
PEMBROLIZUMAB plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PATIENTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: BEVACIZUMAB SUBGROUP ANALYSIS BASED ON PROTOCOL-SPECIFIED FINAL OVERALL SURVIVAL RESULTS OF KEYNOTE-826 Caceres, Valeria Article ISI INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Rha, Sun Young; Oh, Do-Youn; Ryu, Min-Hee; Lee, Jeeyun; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernandez, Manuel Gonzalez; Lowery, Maeve A.; Cil, Timucin; et al. Article ISI SCOPUS The Lancet Oncology (2023)
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047 Hodi, F. S.; Tawbi, H. A.; Lipson, E. J.; Ascierto, P. A.; Matamala, L. A.; Gutierrez, E. C.; Gogas, H. J.; Lao, C. D.; Menezes J.; Arance Fernandez, A. M.; et al. Article ISI ANNALS OF ONCOLOGY (2022)
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma Tawbi, Hussein A.; Lipson, Evan J.; Ascierto, Paolo A.; Gutierrez, Erika Castillo; Rutkowski, Piotr; Gogas, Helen J.; Lao, Christopher D.; De Menezes, Juliana Janoski; Dalle, Stephane; Arance, Ana; et al. Article ISI SCOPUS New England Journal of Medicine (2022)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Pratley, Richard; Lopes, Renato D.; Lam, Carolyn S. P.; Khurmi, Nardev S.; Del Prato, Stefano; AMPLITUDE-O Trial Investigators Article ISI NEW ENGLAND JOURNAL OF MEDICINE (2021)
Consensus on the Treatment and Follow-Up for the Nonmetastatic Castration-Resistant Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries Toledo Pereira, Felipe Moraes; Goncalves e Silva, Adriano; Abbade Dettino, Aldo Lourenco; Garcia Cardoso, Ana Paula; Sasse, Andre Deeke; Kann, Ariel Galapo; Dzik, Carlos; Herchenhorn, Daniel; Fontes Jardim, Denis Leonardo; Lopera, Diego; et al. Article ISI SCOPUS JCO Global Oncology (2021)
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649. Moehler, Markus H.; Garrido, Marcelo; Bragagnoli, Arinilda Silva Campos; Yanez, Patricio Eduardo; Memaj, Arteid Article ISI JOURNAL OF CLINICAL ONCOLOGY (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Garrido, Marcelo; Cullen, Dana Article ISI SCOPUS The Lancet (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Paz-Ares, Luis; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Zurawski, Bogdan; Menezes, Juliana; Richardet, Eduardo; Bennouna, Jaafar; Juan-Vidal, Oscar; Alexandru, Aurelia; Sakai, Hiroshi; et al. Article ISI SCOPUS The Lancet Oncology (2021)
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1 Lee, Jong-Seok; Audigier-Valette, Clarisse; Linardou, Helena; Otterson, Gregory A.; Nishio, Makoto; Jimenez, Emmanuel de la Mora; Lesniewski-Kmak, Krysztof; Albert, Istvan; Ahmed, Samreen; Penrod, John R.; et al. Article ISI SCOPUS Journal of Thoracic Oncology (2021)
KEYNOTE-826: PEMBROLIZUMAB PLUS CHEMOTHERAPY VERSUS PLACEBO PLUS CHEMOTHERAPY FOR PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER Tewari, K; Keefe, S.; Monk, B Article ISI INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer Colombo N.; Dubot C.; Lorusso D.; Caceres, M., V; Shapira-Frommer R.; Tewari, K. S.; Usta, E. Hoyos; de Mendoza, M. Olivera Hurtado; Samouëlian, V; Castonguay V.; et al. Article ISI SCOPUS New England Journal of Medicine (2021)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study Hoyos, E. Article ISI ANNALS OF ONCOLOGY (2021)
Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study Moehler M.; Yamaguchi K.; Skoczylas T.; Campos Bragagnoli A.; Yanez P.; Tehfe M.; Poulart V.; Ajani, J. A.; Janjigian, Y. Y. Article ISI ANNALS OF ONCOLOGY (2020)
Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1 Brahmer, J. R.; Zurawski B.; Otterson, G. A.; de la Mora Jimenez E.; Lesniewski-Kmak K.; Albert I.; Feeney K.; Frickhofen, N.; Hellmann, M. Article ISI ANNALS OF ONCOLOGY (2020)
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial Motzer, Robert J.; Melichar, Bohuslav; Gruenwald, Viktor; Ravaud, Alain; Geertsen, Poul F.; Tomita, Yoshihiko; Saggi, Shruti Shally Article ISI SCOPUS Journal for ImmunoTherapy of Cancer (2020)
Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: Impact on pathological complete response and safety Villanueva L.; Anabalon J.; Butte J.M.; Salman P.; Panay S.; Milla E.; Gallardo C.; Hoefler S.; Charles R.; Reyes F.; et al. Article ISI SCOPUS ecancermedicalscience (2020)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Motzer, Robert; Rini, Brian, I; McDermott, David F.; Frontera, Osvaldo Aren; Hammers, Hans J.; Escudier, Bernard; Beuselinck, Benoit; Amin, Asim; Porta, Camillo; George, Saby; et al. Article ISI LANCET ONCOLOGY (2019)
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America Queiroz Muniz D.; Jenkins M.; Signorovitch J.; Dezzani L.; Lema Medina M.; Lopera D.; Campos-Gomez S. Article ISI SCOPUS ADVANCES IN THERAPY (2019)
Complete preoperative chemotherapy regimen FLOT: Evaluating the safety and histopathologic results in gastric cancer (GC). Villanueva, Luis; Gallardo, Carlos; Reyes, Felipe; Charles, Roberto; Enrique Panay, Sergio; Alejandra Munoz, Maria Article ISI JOURNAL OF CLINICAL ONCOLOGY (2018)
Evidence of response to pembrolizumab in a patient with lynch syndrome-related metastatic colon cancer Panay S.; Mahave M. Article ISI SCOPUS (2018)
Nivolumab (nivo) plus ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227 Ciuleanu, Tudor Eliade; Pluzanski, Adam; Lee, Jong Seok; Otterson, Gregory; Minenza, Elisa; Burgers, Sjaak; Borghaei, Hossein; Ramalingam, Suresh S.; Brahmer, Julie; O'Byrne, Kenneth J.; et al. Article ISI CANCER RESEARCH (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden Hellmann M.D.; Ciuleanu T.E.; Pluzanski A.; Lee J.S.; Otterson G.A.; Audigier-Valette C.; Minenza, E; Linardou H.; Burgers, S; Borghaei H.; et al. Article ISI SCOPUS NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Frontera O.A.; Salman P.; Gurney H.; Hawkins, R; Ravaud A.; Grimm M.O.; Barrios C.H.; Tomita Y.; Chen, AC; Wind-Rotolo, M; et al. Article ISI SCOPUS NEW ENGLAND JOURNAL OF MEDICINE (2018)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer von Minckwitz, Gunter; Procter, Marion; de Azambuja, Evandro; Zardavas, Dimitrios; Benyunes, Mark; Suter, Thomas; Arahmani, Amal; Rouchet, Nathalie; Clark, Emma; Knott, Adam; et al. Article ISI NEW ENGLAND JOURNAL OF MEDICINE (2017)
Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial Agbor-Tarh D.; Bradbury I.; Di Cosimo S.; Sarp S.; Wolff A.C.; Kroep J.; Cufer T.; Simon S.D.; Gralow J.; Moreno-Aspitia A. Article ISI SCOPUS JOURNAL OF CLINICAL ONCOLOGY (2017)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial Jeziorski K.; Shparyk Y.; Sobrero A.; Salman P.; Li J.; Protsenko S.A.; Wainberg, Z. A.; Buyse M.; Afenjar K.; Houè V.; et al. Article ISI SCOPUS JOURNAL OF CLINICAL ONCOLOGY (2016)
The initial Chilean experience with 68Ga/177Lu-PSMA in castration resistant prostate cancer Ribbeck, Jessica Article World Journal of Nuclear Medicine (Online) (2016)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Choueiri, T. K.; Mainwaring, P. N.; Rini, B. I.; Hutson, T. E.; Lee J.L.; Peltola K.; Roth, B. J.; Geczi, L.; Keam, B.; Maroto, P.; et al. Article ISI NEW ENGLAND JOURNAL OF MEDICINE (2015)
Post-hoc analyses of overall survival (OS) and progression-free survival (PFS) in the TRIO-013/LOGiC trial of lapatinib (L) in combination with capecitabine plus oxaliplatin (CapeOx) Bang, Yung-Jue; Chung, Hyun-Choel; Jeziorski, Krzysztof; Shparyk, Yaroslav; Hoff, Paulo M.; Sobrero, Alberto F.; Protsenko, Svetlana; Buyse, Marc E.; Afenjar, Karen; Houe, Vincent; et al. Article ISI JOURNAL OF CLINICAL ONCOLOGY (2015)
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update Sternberg, CN; Hawkins, RE; Wagstaff, J; Salman P.; Mardiak J.; Barrios C.H.; Zarba J.J.; Gladkov, OA; Lee E.; Szczylik C.; et al. Article ISI SCOPUS European Journal of Cancer (2013)
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial Kang, Yoon-Koo; Chung, Hyun-Cheol; Oh, Sang Cheul; Bodoky, Gyoergy; Kurteva, Galina; Volovat, Constantin; Moiseyenko, Vladimir M.; Gorbunova, Vera; Park, Joon Oh; Sawaki, Akira; et al. Article ISI LANCET ONCOLOGY (2013)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Sternberg, CN; Davis I.D.; Mardiak J.; Szczylik C.; Lee E.; Wagstaff, J; Barrios C.H.; Salman P.; Gladkov, OA; Kavina, A; et al. Article ISI JOURNAL OF CLINICAL ONCOLOGY (2010)
BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST Canals L, Mauricio; Fernández G, Monzerrat; Barros R, Adolfo; Mahave C, Mauricio; Salman B, Pamela; Yañez G, Manuel Article SCIELO Revista chilena de radiología (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Pirker, Robert; Pereira, Jose R.; Szczesna, Aleksandra; von Pawel, Joachim; Krzakowski, Maciej; Ramlau, Rodryg; Vynnychenko, Ihor; Park, Keunchil; Yu, Chih-Teng; Ganul, Valentyn; et al. Article ISI LANCET (2009)
Diagnosis of pneumonia and monitoring of infection eradication Ruiz M.; Arosio C.; Salman P.; Bauer, TT; Torres A. Article ISI DRUGS (2000)
MALT lymphoma of the bladder: report of a case Gamargo, C; COMPARINI B. Article REVISTA MEDICA DE CHILE (1998)


Prospective Epidemiological Study of Metastatic Non-Small Cell Lung Cancer (NSCLC) in Latin America - LATINO Lung (LACOG 0116) Werutsky G.; Cardona A.F.; Arrieta, OG; Gelatti, A; Mathias C.; Zukin, M; Cronemberger, E; Mascarenhas, E; de Lima V.C.; Araujo, LH; et al. Abstract ISI JOURNAL OF THORACIC ONCOLOGY (2019)
Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). Frontera O.A. Abstract ISI JOURNAL OF CLINICAL ONCOLOGY (2019)
Global Cancer Institute multidisciplinary tumor boards as a tool to improve patterns of clinical practice for breast and gynecologic cancer in resource-limited settings. Louis, J; Bukowski, A; Rodrigues, AN; De La Serna, F; Tindwa, CH; Mollah, OB; Villarreal-Garza C.; Hambardzumyan, V; Soria T.; Goss, PE Abstract ISI JOURNAL OF CLINICAL ONCOLOGY (2017)
Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). Escudier, BJ; Motzer R.J.; Powles T.; Tannir N.M.; Donskov F.; Grunwald, V; Heng, DYC; Hutson, T; Melichar B.; Nosov, D; et al. Abstract ISI JOURNAL OF CLINICAL ONCOLOGY (2016)


Association of biomarkers with response to coformulated vibostolimab/pembrolizumab (vibo/pembro) in metastatic cervical cancer (CC): Exploratory analysis from the phase II KEYVIBE-005 study Ghiringhelli F.; Rha S.Y. ConferencePoster (2024)
Association of biomarkers with response to first-line (1L) vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in advanced head and neck squamous cell carcinoma (HNSCC): Results from KEYVIBE-005 Calderón B.; Chou, HH; Ghiringhelli F.; Le Tourneau, C ConferencePoster ISI ANNALS OF ONCOLOGY (2024)
Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial Vjaters, E; Shore, ND; Olmos, D; Xing, N; Gomes, A.J.P.D.S.; Mota, A.C.A.; Jievaltas, M; Ulys, A et al ConferencePoster ISI ANNALS OF ONCOLOGY (2024)
Patient-reported outcomes (PROs) with coformulated vibostolimab/pembrolizumab (vibo/pembro) for metastatic cervical cancer (CC): Results from the KEYVIBE-005 study Ghiringhelli F.; Dongen, MV; Kwiatkowski M.; Rha S.Y. ConferencePoster (2024)
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer ConferencePoster ISI INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2024)
Safety and efficacy of vibostolimab (anti-TIGIT) coformulated with pembrolizumab (vibo/pembro) in previously untreated advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II KEYVIBE-005 study Chou, HH; Ghiringhelli F. ConferencePoster ISI ANNALS OF ONCOLOGY (2024)
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer ConferencePoster (2023)
A multicohort, open-label, phase 2 basket study of the coformulation of vibostolimab with pembrolizumab, with or without other anticancer therapies, in select solid tumors Gonzalez, Lucia ConferencePoster (2022)
NIVO + RELA vs NIVO dans le mélanome métastatique ou non résécable précédemment non traité : survie globale et taux de réponse objective par sous-groupes clés de l’étude RELATIVITY-047 Tawbi H.A.; Hodi, S; Lipson E.J.; Ascierto P.A.; Gutiérrez, P et al ConferencePoster (2022)
Nivolumab (NIVO)+ relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047 Ascierto, Paolo; Castillo, Erika; Gogas, Helen ConferencePoster (2022)
Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (023) Monk, Bradley; Tewari, Krishnansu; Gümü?, Mahmut; Olivera, Mivael et al ConferencePoster (2022)
Pembrolizumab+ chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826 Gumus, Mahmut et al ConferencePoster (2022)
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047) Long, Georgina; Lipson, Evan; Ascierto, Paolo Antonio; Castillo, Erika; Rutkowski, Piotr et al ConferencePoster (2022)
LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis Pluzanski A.; Havel, L et al ConferencePoster (2019)
CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups Frontera O.A. ConferencePoster (2017)
Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study Bodoky, Gyorgy; Kurteva, Galina Petrova; Volovat, Constantin D; Sawaki, Akira et al ConferencePoster (2013)
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial J Randolph Hecht,; Qin, Shukui K; Chung, Hyun C; Xu, Jianming M; Park, Joon O; Sobrero, Alberto ConferencePoster (2013)
Cetuximab in combination with capecitabine and cisplatin as first-line treatment in advanced gastric cancer: Randomized controlled phase III EXPAND study Lordick F.; Bodoky, G; Kurteva, G; Kang, YB; Oh, SC; Goette, H; Melezinkova, H ConferencePoster (2012)
A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) Sternberg, CN; Szczylik C.; Davis I.D.; Pandite, L; McCann, L.; Hawkins, R ConferencePoster (2009)
Patient-reported outcomes from the phase III, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 Study of pembrolizumab plus concurrent chemoradiotherapy among patients with high-risk, locally advanced cervical cancer Salani, Ritu ConferencePoster


Carvedilol for anthracycline cardiomyopathy prevention Florenzano F.; Salman P. Letter ISI JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)


A molecular subtype associated with p53 alterations identifies gastric cancer patients with poor response to chemotherapy plus immunotherapy treatments Garrido, Marcelo Proyecto (2022)
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649) Bristol-Myers Squibb; Janjigian Y.Y.; Skoczylas T, et al. Proyecto (2016)


Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective de Melo, Andreia Cristina; Rico-Restrepo, Mariana; Rodriguez, Jeronimo; Russi, Andrea; Schmerling, Rafael Aron; Zambrano, Angela; Cinat, Gabriela Review ISI SCOPUS Frontiers in Oncology (2023)
Unraveling the complex link between vitamin D levels and cancer: A crucial understanding for designing future supplementation approaches Review ISI SCOPUS Brazilian Journal of Pharmaceutical Sciences (2023)